Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 10/20 | 0.78 |
| ▸ | FNTB | P49356 | 10/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.57 |
| ▸ | RORC | P51449 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12022163 | 1.00 | FNTA (0.78) | FNTAFNTBCYP3A4RORC | |
| SCHEMBL12022161 | 1.00 | FNTA (0.78) | FNTAFNTBCYP3A4RORC | |
| SCHEMBL6585485 | 0.94 | FNTA (0.68) | FNTAFNTBCYP3A4RORC | |
| SCHEMBL7174159 | 0.92 | FNTA (0.80) | FNTAFNTBCYP3A4RORC | |
| SCHEMBL5722562 | 0.91 | FNTA (0.78) | FNTAFNTBCYP3A4RORC | |
| SCHEMBL1643357 | 0.91 | FNTA (0.78) | FNTAFNTBCYP3A4RORC | |
| SCHEMBL7256220 | 0.91 | FNTA (0.78) | FNTAFNTBCYP3A4RORC | |
| SCHEMBL5722541 | 0.91 | FNTA (0.78) | FNTAFNTBCYP3A4RORC | |
| Cp-609754 SCHEMBL21055098 | 0.90 | FNTA (0.81) | FNTAFNTBCYP3A4RORC | |
| Cp-609754 SCHEMBL30481066 | 0.90 | FNTA (0.81) | FNTAFNTBCYP3A4RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1107963-B1 | ALKYNYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PROD INC (US) | 2006-03-22 | — | — | EP | claimed |
| US-20020128287-A1 | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents | LYSSIKATOS JOSEPH P (US) | 2002-09-12 | — | — | US | claimed |
| CN-1314904-A | Alkynyl-substituted quinoline-2-one derivatives useful as anticancer agents | PFIZER PROD INC (US) | 2001-09-26 | — | — | CN | claimed |
| EP-1107963-A1 | ALKYNYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-06-20 | — | — | EP | claimed |
| US-6150377-A | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents | PFIZER INC. (US) | 2000-11-21 | — | — | US | claimed |
| WO-2000012499-A1 | ALKYNYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2000-03-09 | — | — | WO | claimed |
| US-8232402-B2 | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications | LINK MEDICINE CORPORATION (US) | 2012-07-31 | — | — | US | disclosed |
| WO-2009151683-A2 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | LINK MEDICINE CORPORATION (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090253655-A1 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | ASTRAZENECA AB (SE) | 2009-10-08 | — | — | US | disclosed |
| EP-1107963-B1 | ALKYNYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PROD INC (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20050020836-A1 | Crystal forms of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4(3-ethynyl-phenyl)-1methyl-1h-quinolin-2-one, 2,3,-dihydroxybutanedioate salts and method of production | PFIZER INC. | 2005-01-27 | — | — | US | disclosed |
| US-6734308-B2 | AZEOTROPIC REMOVAL OF WATER; ANTIPROLIFERATIVE AND ANTICARCINOGENIC AGETNS | PFIZER INC | 2004-05-11 | — | — | US | disclosed |
| EP-1395577-A1 | CRYSTAL FORMS OF 6- (4-CHLORO-PHENYL)-HYDROXY-(-3-METHYL-3H-IMIDAOL-4-YL)-METHYL]-4-(3-ETHYNYL-PHENYL)-1-METHYL-1H-QUINOLIN-2-ONE, 2,3-DIHYDROXYBUTANEDIOATE SALTS AND METHOD OF PRODUCTION | Pfizer Products Inc. (US) | 2004-03-10 | — | — | EP | disclosed |
| US-20020128287-A1 | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents | LYSSIKATOS JOSEPH P (US) | 2002-09-12 | — | — | US | disclosed |
| WO-2002050058-A1 | CRYSTAL FORMS OF 6-[(4-CHLORO-PHENYL) -HYDROXY-(-3-METHYL- 3H-IMIDAOL-4-YL) -METHYL] -4-(3-ETHYNYL-PHENYL) -1-METHYL-1H- QUINOLIN-2-ONE, 2,3- DIHYDROXYBUTANEDIOATE SALTS AND METHOD OF PRODUCTION | PFIZER PRODUCTS INC. (US) | 2002-06-27 | — | — | WO | disclosed |
| CN-1314904-A | Alkynyl-substituted quinoline-2-one derivatives useful as anticancer agents | PFIZER PROD INC (US) | 2001-09-26 | — | — | CN | disclosed |
| US-6294552-B1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS, SUCH AS CANCER, IN MAMMALS. THE INVENTION ALSO RELATES TO METHODS OF INHIBITING ABNORMAL CELL GROWTH, INCLUDING CANCER, IN A MAMMAL BY ADMINISTERING THE COMPOUNDS OF FORMULA 1 TO A MAMMAL REQUIRING | PFIZER INC. | 2001-09-25 | — | — | US | disclosed |
| EP-1107963-A1 | ALKYNYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-06-20 | — | — | EP | disclosed |
| US-6150377-A | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents | PFIZER INC. (US) | 2000-11-21 | — | — | US | disclosed |
| WO-2000012499-A1 | ALKYNYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253655-A1 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | PANK1, PANK3, PANK2 | FNTA 4/4885FNTB 19/4885CYP3A4 3795/4885 |
| US-20050020836-A1 | Crystal forms of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4(3-ethynyl-phenyl)-1methyl-1h-quinolin-2-one, 2,3,-dihydroxybutanedioate salts and method of production | RCC1, VHL, MCL1 | FNTA 2949/4885FNTB 3994/4885CYP3A4 452/4885 |
| US-20020128287-A1 | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents | CCNA1, NRAS, CCNT1 | FNTA 1890/4885FNTB 2727/4885CYP3A4 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.